metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
limited stage SCLC (ls-SCLC) - maintenance (M) limited stage SCLC (ls-SCLC) limited stage SCLC (ls-SCLC) - maintenance (M)
versus no additional treatment
	nivolumab plus ipilimumab
	STIMULI unpublished Ann Oncol. 2022 Jan;33(1):67-79 NCT02046733	RCT	limited stage SCLC (ls-SCLC) - maintenance (M)	nivolumab plus ipilimumab	no treatment added	limited stage SCLC patients who had undergone chemoradiotherapy treated as consolidation treatment	78 / 75	NA	inconclusive	inconclusive 5 % decrease in deaths (OS) (PE) inconclusive 2 % increase in progression or deaths (PFS) (PE) statistically significant 3.1-fold increase in AE (grade 3-4) The immunotherapy combination nivolumab plus ipilimumab did not significantly improve progression-free survival (PFS) or overall survival.